Immune checkpoint inhibitors in non-small-cell lung cancer: key to long-term survival?

A-M C. Dingemans*, L. E. L. Hendriks

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

Original languageEnglish
Pages (from-to)291-292
Number of pages2
JournalThe Lancet Respiratory medicine
Volume7
Issue number4
DOIs
Publication statusPublished - Apr 2019

Keywords

  • PEMBROLIZUMAB

Cite this